Sugi Predict

Sugi Predict / Compounds / SCHEMBL28004

SCHEMBL28004

SCHEMBL28004

CS(=O)(=O)c1cccc(C(=O)O)c1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.58
▸ GAA P10253 2/20 0.58
▸ HSD17B10 Q99714 1/20 0.58
▸ F2 P00734 3/20 0.57
▸ PRSS1 P07477 3/20 0.57
▸ PRSS2 P07478 3/20 0.57
▸ PRSS3 P35030 3/20 0.57
▸ CA1 P00915 1/20 0.57
▸ CA2 P00918 1/20 0.57
▸ MAPT P10636 1/20 0.56
▸ IL1RN P18510 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ CYP2C19 P33261 1/20 0.54
▸ AKR1C3 P42330 2/20 0.53
▸ AKR1C1 Q04828 1/20 0.53
▸ MEP1B Q16820 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29453108 1.00 ALDH1A1 (0.58) ALDH1A1GAAHSD17B10F2PRSS1
Hydrochloric Acid SCHEMBL35358 0.98 ALDH1A1 (0.56) ALDH1A1GAAHSD17B10F2PRSS1
SCHEMBL4252833 0.89 KMO (0.59) ALDH1A1GAAHSD17B10F2PRSS1
SCHEMBL27781055 0.86 SMN1; SMN2 (0.57) ALDH1A1GAAHSD17B10SMN1; SMN2
SCHEMBL11795859 0.85 ALDH1A1 (0.55) ALDH1A1GAAHSD17B10F2PRSS1
SCHEMBL16094602 0.85 F2 (0.54) ALDH1A1F2PRSS1PRSS2PRSS3
SCHEMBL14501007 0.84 SMN1; SMN2 (0.68) ALDH1A1GAASMN1; SMN2
SCHEMBL212547 0.84 ALDH1A1 (0.57) ALDH1A1GAAHSD17B10SMN1; SMN2
SCHEMBL29964265 0.83 F2 (0.61) ALDH1A1F2PRSS1PRSS2PRSS3
SCHEMBL2405304 0.83 F2 (0.61) ALDH1A1F2PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 729 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025202864-A1 ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER iTeos Belgium SA (BE) 2025-10-02 — — WO claimed
WO-2025126110-A1 ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES iTeos Belgium SA (BE) 2025-06-19 — — WO claimed
WO-2025104613-A1 ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS iTeos Belgium SA (BE) 2025-05-22 — — WO claimed
CN-116535365-A Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer ITEOS比利时公司 2023-08-04 — — CN claimed
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-06-29 — — US claimed
EP-4132933-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-02-15 — — EP claimed
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 — — EP claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 — — EP claimed
WO-2025202864-A1 ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER iTeos Belgium SA (BE) 2025-10-02 — — WO disclosed
US-20250257041-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2025-08-14 — — US disclosed
US-12383560-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-12 — — US disclosed
WO-2025126110-A1 ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES iTeos Belgium SA (BE) 2025-06-19 — — WO disclosed
WO-2025104613-A1 ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS iTeos Belgium SA (BE) 2025-05-22 — — WO disclosed
CN-118684605-A Preparation of ritgasan Process for the preparation of intermediates 山东新时代药业有限公司 2024-09-24 — — CN disclosed
EP-0093484-A2 Antibacterial monic acid derivatives BEECHAM GROUP PLC (GB) 1983-11-09 — — EP disclosed
US-4324898-A YELLOW COUPLER CIBA GEIGY AG (CH) 1982-04-13 — — US disclosed
US-4229577-A IMPROVED REACTIVITY, MINIMAL FOG, HIGH FASTNESS TO LIGHT CIBA-GEIGY AG (CH) 1980-10-21 — — US disclosed
US-4206278-A SILVER HALIDE, HETEROCYCLIC YELLOW COUPLER CIBA-GEIGY AG (CH) 1980-06-03 — — US disclosed
US-4115121-A TWO-EQUIVALENT BENZOYLACETANILIDE METHYLENE COUPLERS CIBA-GEIGY AG (CH) 1978-09-19 — — US disclosed
US-3947450-A Benzoxanthene and benzothioxanthene dicarboxylic acid imide dyestuffs and process for their manufacture HOECHST AKTIENGESELLSCHAFT (DT) 1976-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS ENTPD1, SLC29A1, ENTPD5 ALDH1A1 357/4885GAA 2143/4885HSD17B10 4191/4885
US-20250257041-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER DDIT3, ATF4, EIF2AK3 ALDH1A1 4205/4885GAA 3353/4885HSD17B10 2778/4885
US-12383560-B2 Compounds and uses thereof VHL, CLN6, TFEB ALDH1A1 2571/4885GAA 9/4885HSD17B10 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.